consistently neutralized primary HIV-1 strains in cocultures of PBMC from HJV-1 -infected persons as determined by suppression of HIV-1 p24 core antigen accumulation in culture supernatants and cells.
MATERIALS AND METHODS
RBC-CD4 were prepared as described previo~sly.'~-'~ Briefly, CD4 was purified from cultures of insect cells infected with Autograph California polyhedrosis baculovirus encoding human transmembrane CD4.I' CD4 was electroinserted into human erythrocytes isolated from citrated blood; RBC-CD4 were introduced into culture within 24 hours of electroinsertion. RBC from a single pool electroinserted with CD4 or untreated were used in parallel in each experiment.
HIV-1+ subjects in New York (site 1) were recruited from participants in the St Luke'sRoosevelt AIDS Clinical Trial Group (ACTG). Subjects in Baltimore (site 2) were recruited from individuals attending the Johns Hopkins Moore AIDS Clinic and their clinical status is listed in Table 3 . No attempt was made to select patients by their CD4 levels, symptom status, or treatment.
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HIV-1-subjects were recruited from within the laboratories. Informed consent was obtained from all donors.
The laboratory strain HIV-l/NlT was obtained and concentrated from supernatants of chronically infected CRl O/NlT cells and titered as previously described,22 and stored in aliquots at -80°C until use.
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque (Phannacia, Piscataway, NJ) density gradient centrifugation from heparinized blood within 4 hours of collection from all donors. For studies at site 1, HIV-1-PBMC were stimulated with 5 pg/mL phytohemagglutinin (PHA; Sigma, St Louis, MO) and 10 U/mL interleukin-2 (IL-2; Biotest, Denville NJ) in RPMI-1640 for 2 to 3 days and washed before coculture with PBMC isolated from HIV-1 -infected persons. Two units per milliter of IL-2 (Sigma) was used at site 2. Cocultures contained 0.5 X lo6 cells in 1 mL RPMI-1640 medium containing IL-2 at a 1 5 or a 1:lO ratio of infected to uninfected cells and either rsCD4 (donated by Genentech, South San Francisco, CA), baculovirus-derived transmembrane CD4 (bCD4), RBC, or RBC-CD4, as indicated in the figures or in the text. All inhibitors were added immediately after cell mixing. bCD4 was used as a suspension in culture medium; previous studies have shown that it is active in this form as an inhibitor of infection with a laboratory strain of HIV-1 (DJ Volsky, unpublished results, 1995). Cultures were maintained for 10 to 20 days, inhibitors were replaced in the cultures weekly at starting concentrations, and cultures were sampled regularly for cell viability and p24 production. When indicated, 5'-azidothymidine ( U T , a gift of Burroughs-Wellcome CO, Research Triangle Park, NC) or 2', 3'-dideoxycytidine (ddC; Sigma) were used at 1 pmoVL.
The content of HIV-1 p24 core antigen in culture supematants or cell lysates was determined using Coulter HIV Ag kits (Coulter, Hialeah, FL) according to the manufacturer's instructions. For cell-associated p24 determination, total culture cells (including RBC or RBC-CD4 when present in the culture) were sedimented at 400g for 10 minutes, washed, lysed in a Coulter p24 lysis buffer containing detergent at 1 X lo6 live PBMC/O.l mL, and assayed using Coulter HIV Ag kit. The results are expressed in picograms of p24 antigen per 1 X lo6 live PBMC (site 1) or as p24 in total cell lysate from cells of 1 mL culture (site 2).
Virus.
Cultures for the transmission of primary HIV-1 strains.
Assay of virus production and reagents.

RES U LTS
Characterization of RBC-CD4 as decoys for primary HI V-1 in vitro: RBC-CD4 dose response, kinetics, and specijcity of inhibition. We have previously shown that preincubation of a laboratory HIV-1 strain with RBC-CD4, but not with RBC-CD4 blocked with OKT4A, significantly reduced virus infectivity in cultured T cells." Here we tested the antiviral activity of RBC-CD4 directly in an in vitro infection assay designed to maximize transmission and replication of primary HIV-1 strains in PBMC. In this assay, patient PBMC are cocultivated with uninfected stimulated PBMC at 1 5 or 1:lO ratio. Because of an excess of uninfected cells, any increase in virus levels measured in this assay results mostly from new infection events by virus produced in patient PBMC. RBC-CD4 present in the coculture are expected to trap or neutralize the extracellular virus, thus preventing virus spread to uninfected cells.
To determine the RBC-CD4 dose required for maximum neutralization in this assay, we established cocultures of PBMC from an HIV-1-infected individual (patient 1, site 1) with HIV-1-PHA-stimulated blasts at a ratio of 1 5 , respectively, and added at the time of cell mixing rsCD4, bCD4 (the same preparation as that used for electroinsertion), RBC, or RBC-CD4 in varying amounts. Each culture was established in duplicate. After 10 days, culture supernatants were collected and assayed for HIV-1 p24 core antigen content. Figure 1 shows the average p24 levels of the duplicate cultures. It is clear that RBC-CD4 prevented the accumulation of supernatant p24 in this system in a dose-dependent manner; the 50% inhibitory dose in this experiment was 2 X IOs RBC-CD4 per culture system containing 2 X lo5 patient PBMC/mL. RBC-CD4 contained about 10 ng inserted CD4 per 2 X lo8 cells (not shown). Neither rsCD4 nor bCD4 was an efficient inhibitor of p24 accumulation in cocultures of patient 1 cells in this assay. We conclude that the presence of RBC-CD4 during cocultivation of patient lymphocytes with uninfected PBMC in vitro efficiently neutralizes primary HIV-1, most likely by trapping extracellular HIV-1 particles and preventing their access to uninfected cells.
We next tested whether RBC-CD4 were able to neutralize primary HIV-1 during the entire course of PBMC cocultivation. We established cocultures of PBMC from another HIV-1 -infected patient (patient 7, site 1) and from an uninfected person in the presence of RBC-CD4, RBC, bCD4, or no inhibitor, and sampled HIV-1 p24 in culture supernatants at day 5, 10, and 15 ( RBC-CD4 inhibited p24 accumulation throughout the 15 days of culture. Cell viability was similar in RBC-and RBC-CD4 containing cultures throughout the period of observation. These results indicate that neutralization of cell-free HIV-1 by RBC-CD4 is long-lived, presumably because of the long half-life of RBC-CD4 and stabiIity of electroinserted transmembrane recombinant CD4.'9s20
To determine whether the observed reduction in p24 accumulation in supernatants of cultures with RBC-CD4 (Figs 1 and 2) reflected a decrease in both cell-free and cell-associated virus in our cocultivation system, we established cocultures of PBMC from several HIV-1 -infected patients at both sites with or without HIV-1 inhibitors as described above and evaluated the levels of p24 core antigen in both culture supematants and total cell lysates (Table 1) . Cells were sedimented at 400g for 10 minutes so that the pellets analyzed contained both PBMC and RBC or RBC-CD4 when present. In each case shown, a reduction in p24 levels in culture supematants in the presence of RBC-CD4 was accompanied by a similar reduction in intracellular p24 in the same culture (Table 2 ). Consistent with the data shown in Figs 1 and 2 , RBC, sCD4, and bCD4 were not efficient inhibitors of p24 accumulation; both supernatant and intracellular p24 levels in these cultures were similar to those measured in cultures without any inhibitors (samples 1 through 3 in Table 2 ). Addition of ddC, a potent inhibitor of reverse transcription, 
Samples 1-3: patient 1, 5, and 7 PBMC cultures, respectively, from the virus transmission experiments at site 1 shown in Fig 3, were evaluated for both supernatant and cell-associated HIV-1 p24 core antigen at the peak of infection as described in Materials and Methods.
Samples 4 and 5 were evaluated similarly at site 2 using 5 x 10' RBC or RBC-CDQ/mL. At both sites, total cell pellets included both PBMC and RBC or RBC-CD4, when present.
* For samples 1-3, the results are expressed as pg p24/10' cells; for samples 4 and 5, the results represent p24 in total cell lysate from cells sedimented from a 1 mL culture, resuspended in 1 mL medium, and assayed. ddC was used at 1 pmol/L, and sCD4 and bCD4 at 10 pg/mL culture. 1 pg p24 N I T was exposed to the indicated number of RBC-CD4 or RBC for 1 hour at 37°C. Cells were washed three times and assayed for p24 binding. Ratio: ratio of p24 bound by RBC-CD4 to p24 bound by RBC for log or IO' cells, respectively.
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TOSl ET AL resulted in complete block of p24 production, indicating that most of the p24 production detected in this cocultivation system results from spreading of cell-free and cell-associated virus from patient PBMC to uninfected cells and virus replication in these cells. These data indicate that RBC-CD4 efficiently inhibits transmission of HIV-1 to uninfected cells, presumably by binding and fusing with" virus produced by donor lymphocytes.
To confirm the specificity of the interaction of RBC-CD4 with HIV-1, we exposed RBC or RBC-CD4 to concentrated HIV-UNIT (a laboratory isolate) and determined the binding of virus by measuring p24 adsorbed to these cells (Table  2 ). In two experiments, using different electroinserted cell preparations, RBC-CD4 bound roughly 10-fold more p24 than control RBC, indicating that RBC-CD4 have enhanced affinity for HIV-1. We have shown previously that HIV-1 fused efficiently with RBC-CD4, but not with RBC." Together, the data in Figs 1 and 2 and Tables 1 and 2 indicate that electroinsertion of transmembrane CD4 into fresh RBC membranes converts the cells into decoy targets for both laboratory and primary HIV-1. Like other CD4+ cells, RBC-CD4 interact with HIV-1 produced by donor PBMC and compete with uninfected PBMC in a cocultivation assay, blocking HIV-I infection of these cells. The present data do not allow us to distinguish whether these effects of RBC-CD4 are caused by trapping of extracellular HIV-1 particles or blocking cell-to-cell transmission of virus, or both.
Generality and reproducibility of neutralization of primary HIV-1 by RBC-CD4. To determine whether RBC-CD4 can neutralize the infectivity of HIV-1 from a variety of infected donors, we prepared cocultures using PBMC from 8 HIV-1-infected persons at site I (Fig 3) and from 15 HIV-I-infected individuals at site 2 ( Table 3 ). The RBC-CD4 for the experiments at site 1 were used within 1 day of preparation; RBC-CD4 for the experiments at site 2 were prepared on site and used the same day. The clinical status of the patients at site 1 ranged from asymptomatic to acquired immunodeficiency syndrome (AIDS), their CD4+ cell levels in blood ranged from 11 to 240 cells/pL, and 4 of 8 patients studied were on antiviral therapy at the time of blood donation. The clinical status and CD4+ T-cell levels of donors at site 2 are listed in Table 3 . Cocultures were established at a 1:10 ratio (patients 4 and 7 at site 1, and all patients at site 2) or 1 5 ratio of infected to uninfected cells. Inhibitors were added immediately after cell mixing. Cultures were supplemented weekly with fresh media and inhibitors at their initial doses and monitored for 3 weeks for p24 production. At site I, all eight donors were sampled once each. The PBMC were tested once over the course of three separate experiments using new RBC-CD4 batches at each time. RBC-CD4 inhibited p24 expression in cocultures in all cases. Figure 3 shows peak p24 values obtained in these experiments. Recombinant soluble CD4 inhibited HIV-I transmission from cells of patient 7, reflecting the heterogeneity of responses of primary HIV-1 strains to rsCD4''.''; bCD4 was not observed to inhibit HIV-I transmission in any of cultures.
Over the course of five independent experiments at site 2, performed according to the same protocol but using locally prepared RBC-CD4, a total of 17 PBMC samples from 15 different patients were evaluated. Two of the 17 samples yielded no transmissible virus, and in 13 of 15 culturable samples RBC-CD4 neutralized patient virus in our virus transmission assay with an efficiency ranging from 70% to over 99% compared with RBC alone. One of the IS individuals was sampled on three different occasions with consistent results (Table 3) . Azidothymidine (AZT) (1 pmoVL) inhibited virus transmission in all samples tested at site 2 (not shown). In two cultures (patients 3 and 7 in Table 3 ), nonspecific inhibition by RBC alone was observed, reducing supernatant p24 to borderline detection levels.
Cocultures were routinely assessed for viability, and RBC or RBC-CD4 at concentrations up to lo9 celldml culture had no distinguishable effect on cell survival. Typically, PBMC cultures (with or without RBC or RBC-CD4) were about 70% viable by day 14, as determined by trypan blue staining (not shown). Taken together, these data show that the inhibition of primary HIV-1 by RBC-CD4 can be demonstrated reproducibly in multiple experiments with PBMC from a single individual (patient 9, Table 3 ) or from different donors, using RBC-CD4 prepared on site or shipped between laboratories.
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From --Virus transmission was tested as described in Materials and Methods: RBC-CD4 and RBC were prepared as described on location at JHU and Abbreviations: NC, negative culture, no virus transmission was detected in control cultures; -, no significant differences were detected Parameters evaluated when blood was donated. t Determined by flow cytometry.
* Determined on day 14 of coculture and calculated using the results from parallel cultures containing RBC as 100% virus transmission. 
DISCUSSION
Our data indicate that RBC-CD4 neutralize, and on a molar basis (compared with soluble CD4), efficiently suppress primary HIV-1 strains in a virus transmission assay in vitro. The anti-HW-1 effect of RBC-CD4 has been shown in 21 of 23 patients and 23 of 25 samples that yielded productive cultures (mean inhibition of 91%). Inhibition was independent of the patient cD4+ cell number, clinical status, or antiviral treatment at the time of blood donation. Thus, RBC-CD4 are powerful inhibitors of primary HIV-1 in culture from a variety of individuals at various stages of HIV-1 disease. Because efficient inhibition was achieved with 2 X 10' RBC-CD4 which contained a total of only about 10 ng CD4, and no inhibition was observed in the presence of 10 pg of transmembrane CD4 not incorporated into cellular membranes (Fig 1) , it appears that display of electroinserted CD4 on RBC membranes results in an improvement in inhibitory capacitj of CD4. Several possibilities could account for this improvement. One is that the two-dimensional matrix array of CD4 molecules in RJ3C membranes may increase CD4 affinity for gp120. A recent study indicates that the relative differences in the ability of rsCD4 to inhibit laboratory isolates and primary isolates may reflect its activity in stages of virus blockade or inactivation which follow CD4-gp 120 binding. l3 Plasma membrane-bound CD4 may be more active in this respect than soluble CD4. Another possibility is that RBC-CD4 have a greater capacity than rsCD4 to induce shedding of gp120 by virions, which is postulated to be a critical step in which primary isolates are differentidy resistant to rsCD4.I' Finally, the greater inhibitory capacity of membrane-bound recombinant CD4 compared with soluble protein could be attributed to the ability of RBC-CD4 to fuse with HIV-1" and to internalize the ~irus,2~ thereby miucing the possibility of release of adsorbed virus back into culture medium. It should be noted in this context that, in contrast to mouse fibroblasts% and certain glioma cell line^,^^,^ display of CD4 on RBC membranes was sufficient to mediate HIV-1 fusion and ent~y.'~,'~ This result indicates that human erythrocyte membranes, l i e those of HeLa cellsM and human glioma H4 cells?7 contain cofactors(s) required for CD4-mediated fusion? ' Whatever the mechanism of HIV-1 neutralization by RBC-CD4, antiviral activity of compounds shown in culture may not predict clinical efficacy. We believe that since the system evaluated here includes transmission of primary HIV-1 by cell-free and cell-to-cell routes, the activity of RBC-CD4 is relevant to natural infection.2ys30 This contrasts with rsCD4, which can inhibit laboratory but not primary isolates of H Nand has not proven to be successful clinially.'^,'^ These results suggest that RBC-CD4 are efficient in blocking or neutralizing virus from HIV-1 -infected PBMC from patients with different disease status and under different drug regimens, providing further indication of the utility of RBC-CD4 as a potential treatment for HIV-1 infection.
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